EU approves Abbott's Humira for pediatric Crohn's disease

11/28/2012 | PharmaTimes (U.K.)

Abbott Laboratories received approval from the European Commission to market Humira, or adalimumab, for patients ages 6 to 17 with severe active Crohn's disease who don't respond to traditional therapy. The approval marks the ninth time that Humira was cleared in the EU.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Executive Medical Director
Aspirus Network Inc
Wausau, WI